BiomedReports: News and FDA Updates for Bristol-Myers (NYSE:BMY), Novelos (OTC:NVLT), Nutra Pharma (OTC:NPHC), Affymetrix (Nasda

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com

On 08/26/09, Bristol-Myers Squibb Company (NYSE: BMY | Quote | Chart | News | PowerRating), announced clinical data added to the labeling for ORENCIA (abatacept) support use of ORENCIA for patients with moderate to severe rheumatoid arthritis of less than or equal to two years duration.

On 08/26/09, Novelos Therapeutics, Inc. (OTC:NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, announced Novelos entered into a definitive agreement with Purdue Pharma L.P., an existing investor, to sell 13,636,364 shares of its common stock and warrants, expiring on December 31, 2015, to purchase an aggregate of approximately 4,772,728 shares of common stock at an exercise price of $0.66 per share, for gross proceeds of $9 million.

On 08/26/09, Nutra Pharma Corp. (OTC:NPHC), a biotechnology company which is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced it has successfully completed a licensing agreement that grants XenaCare Holdings (OTCBB:XCHO) ongoing exclusive United States marketing and distribution rights for Cobroxin in return for meeting specific minimum performance requirements.

On 08/26/09, Affymetrix, Inc. (Nasdaq: AFFX | Quote | Chart | News | PowerRating), and Beckman Coulter, Inc. announced they have entered into an agreement to offer researcher co-developed products from the market leaders in microarrays and automated liquid handlers. The collaboration will provide scientists with optimized, robust solutions for genomic research, fortified by end-to-end support.

Biotech investors interested in seeing more details about these stories and accessing the complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/fda-calendar/fda-calendar.html

Disclosure: No positions.

####

About BiomedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.

For more biomedical sector and investment news, go to www.BioMedReports.com

Certain sections of this report contain forward-looking statements that are based on our reporters' expectations, estimates, projections and assumptions. Words such as "expects" "anticipates" "plans" "believes" "scheduled" "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by the cautionary statements in this section. BiomedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

CONTACT: Mike Havrilla, Managing Editor, BiomedReports.Com
e-mail: mike@biomedreports.com
Tel: +1 323 472 4480
Fax: +1 888 210 3556

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on Bristol-Myers Squibb Co (BMY) BMY. Bristol-Myers Squibb Co (BMY) has Short Term PowerRatings at TradingMarkets. Details on Bristol-Myers Squibb Co (BMY) Short Term PowerRatings is available at This Link.

For full details on Affymetrix Inc (AFFX) AFFX. Affymetrix Inc (AFFX) has Short Term PowerRatings at TradingMarkets. Details on Affymetrix Inc (AFFX) Short Term PowerRatings is available at This Link.

For full details on (NPHC) NPHC. (NPHC) has Short Term PowerRatings at TradingMarkets. Details on (NPHC) Short Term PowerRatings is available at This Link.